22728-89-8

Usage

Uses

Used in Neuroscience Research:
4-Methyl hydrogen D-aspartate hydrochloride is used as a selective agonist for the NMDA receptor to facilitate studies on the receptor's function in memory and learning. Its application aids in the investigation of the receptor's role in neurological conditions such as Alzheimer's disease and schizophrenia, where the NMDA receptor is thought to be implicated.
Used in Pharmaceutical Development:
4-methyl hydrogen D-aspartate hydrochloride is utilized in the development of potential treatments for diseases associated with NMDA receptor malfunction. By selectively stimulating or blocking these receptors, researchers can explore new therapeutic avenues for conditions like Alzheimer's and schizophrenia, where modulating NMDA receptor activity may offer clinical benefits.
Used in Drug Delivery Systems:
In the context of drug delivery, 4-methyl hydrogen D-aspartate hydrochloride may be employed to enhance the targeting and efficacy of medications intended to interact with the NMDA receptor. This could involve the design of drug carriers or delivery systems that can more effectively transport therapeutic agents to the brain, improving their bioavailability and therapeutic outcomes.

InChI:InChI=1/C5H9NO4.ClH/c1-10-4(7)2-3(6)5(8)9;/h3H,2,6H2,1H3,(H,8,9);1H/t3-;/m1./s1

Upstream product

• 67-56-1 methanol 
• 1783-96-6 (2R)-aspartic acid 
• 56-84-8 L-Aspartic acid 

Downstream Products

• 86070-35-1 D-2-amino-3-methylaminopropionic acid 
• 124184-67-4 (2R)-2-[(tert-butoxycarbonyl)amino]-4-methoxy-4-oxobutanoic acid 
• 34582-30-4 L-asparic acid C₁-t-butyl C₄-methyl diester hydrochloride 
• 28862-78-4 (+)-N-Cbz-β-methyl-D-aspartate 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF

The present invention provides a process for preparing (R)-6-(tert-butoxycarbonyl)-6- azaspiro[2.5]octane-5-carboxylic acid (SM1), said process comprising the step of: iv) converting a compound of formula (VII) into a compound of formula (VIII) using a Wittig reagent in a suitable solvent; v) reacting through the Makosza reaction the compound of Formula (VIII) using bromoform and a suitable base to obtain cyclopropane compound of Formula (IX); and vi) removing bromine atoms in the presence of a reducing agent and a base in an alcoholic solvent thus obtaining (SM1). The invention relates also to a process for the conversion of the compound (SM1) for preparing (R)- 4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid (IV) or a salt thereof. The salt is preferably the sodium salt, more preferably the polymorphic form A of sodium (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6- azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9.

Enantioselective Synthesis of a Tricyclic, sp3-Rich Diazatetradecanedione: an Amino Acid-Based Natural Product-Like Scaffold

6-, 7-, and 8-membered rings are assembled from a linear precursor by successive cyclisation reactions to construct a tricyclic diazatricyclo[6.5.1.04, 9]-tetradecanedione scaffold. Advanced building blocks based on d-aspartic acid and l-pyroglutamic acid were combined by a sp3?sp2 Negishi coupling. A carbamate-guided syn-diastereoselective epoxidation followed by an intramolecular epoxide opening allowed the construction of the piperidine ring. An efficient one-pot hydroxyl-group protection twofold deprotection reaction prepared the ground for the cyclisation to the bicycle. A final deprotection of the orthogonal protecting groups and lactamisation led to the novel, sp3-rich tricycle. The final compound is a substrate mimic of peptidyl-prolyl cis-trans isomerases featuring a locked trans-amide bond. Cheminformatic analysis of 179 virtual derivatives indicates favourable physicochemical properties and drug-like characteristics. As proof of concept we, show a low micromolar activity in a fluorescence polarisation assay towards the FK506-binding protein 12.

A convenient method of preparation arab League throws cillin sodium

The invention discloses a convenient method for preparing aspoxicillin sodium. The method comprises the steps of adding D-aspartic acid into a mixed solution of thionyl chloride and methanol, reacting to prepare D-aspartic acid methyl ester hydrochloride, reacting the D-aspartic acid methyl ester hydrochloride with an aqueous solution of methylamine to obtain aspartic formamide, protecting the first amino on the aspartic formamide by using trifluoroacetyl, then reacting the aspartic formamide with carbonyldimidazole to form an active mixed acid anhydride, condensing the active mixed acid anhydride with an amoxicillin triethylamine salt, finally removing the protective ground and forming a sodium salt under the alkali condition to obtain a crude aspoxicillin product of the target product, and refining the crude product to obtain the high-purity aspoxicillin sodium finished product. The method has the advantages that the reagents are cheap, readily available and low in toxicity and environmental pressure, the process operation is compact and stable, the purity of the product is high and the like.

A new kind of diseases and three water vial preparation method of compound

The invention belongs to the field of drug synthesis and discloses a preparation method of a novel amoxicillin trihydrate. The preparation method is characterized in that dibenzothiazyl disulfide as a reaction reagent undergoes a reaction to produce an active ester intermediate, and the active ester intermediate and amoxicillin undergo a condensation reaction to produce a desired compound. The preparation method reduces reaction processes, improves a yield, adopts easily available raw materials, has small dependence on equipment, is conducive to large-scale production, has low reaction toxicity, has small influence on the environment, reduces a production cost, realizes product purity greater than 99% and realizes single impurity content less than 0.2%.

A 10th factor inhibitor and its preparation method and application (by machine translation)

The invention relates to a 10th factor inhibitor and its preparation and application, the 10th factor inhibitor has the structure of formula I, the invention inhibitors to alpha-amino acid as a template, respectively through the amide, carbamate, or urea to the branched chain is formed by a series of novel structure of the compound, this kind of compound can be effectively with the 10th factor binding, prevent the formation of thrombus. (by machine translation)

Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases

Compounds of formula (I) wherein W is —OH or —NHOH; X is an optionally substituted heterocycle, NR1SO2R2, heterocyclylalkythio, CONR2R3or NR1COR2; Y, Z, R1-R3and n are as defined in the application. Compounds (I) are inhibitors of matrix-degrading metalloproteinases and are use for the treatment of related conditions.

Design and preparation of serine-threonine protein phosphatase inhibitors based upon the nodularin and microcystin toxin structures: Part 2. Synthesis of a functionalised nodularin macrocycle and a stripped-down microcystin macrocycle

Nodularins and microcystins are complex natural isopeptidic hepatotoxins that serve as subnanomolar inhibitors of the eukaryotic serine-threonine protein phosphatases, PP1 and PP2A. In Part 1 (A. P. Mehrotra, K. L. Webster and D. Gani, J. Chem. Soc., Perkin Trans. 1, 1997, preceding paper) each of the key structural or potentially reactive motifs within each macrocycle type was assessed as a contributor towards phosphatase inhibitory efficacy and a stripped-down nodularin-type macrocycle was identified as a suitable precursor to potentially active synthetic inhibitors. Subsequently, synthetic routes to the 19-membered nodularin macrocyclic system were developed, using solution-phase chemistry, which demonstrated that only certain cyclisation protocols were viable. Here we describe an extension of this chemistry to provide a 19-membered nodularin macrocycle, cyclo-[(3R)-3-hydroxymethyl-β-Ala-(R)-Glu-α-OMe-γ-Sar-(R)-Asp- α-OMe-β-(S)-Phe-], appropriately functionalised with a hydroxymethyl group for the incorporation of lipophilic side-chains. We also demonstrate that the 25-membered microcystin macrocycle, cyclo-[β-Ala-(R)-Glu-α-OMe-γ-Sar-(R)-Ala-(S)-Leu-(R)-Asp- α-OMe-β-(S)-Phe-], can be prepared in good yield using similar protocols in which macrocyclisation is effected through the reaction of the amino group of the (2S)-phenylalanine residue with the β-pentafluorophenyl ester of the (2R)-aspartic acid residue.

Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: Modification of the P1 and P2' residues

Systematic modification of the presumed P1 side chain in a series of (carboxyalkyl)amino-based inhibitors of matrix metalloproteinases enabled identification of the 2-(1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)ethyl group as a preferred substituent imparting potent inhibition of the enzymes collagenase and gelatinase. It was subsequently found that the P2'-P3' residues in this series could be replaced by small non-peptide residues, while maintaining inhibitory potency. The imide group in this series of compounds can undergo autocatalytic hydrolysis under neutral conditions.